Reproduktive Faktoren und das Ovarialkarzinomrisiko

Kernaussagen

• Das epitheliale Ovarialkarzinom ist die sechsthäufigste Krebsform bei Frauen in Industrieländern.

• Reproduktive Faktoren spielen eine relevante Rolle für das Ovarialkarzinomrisiko.

• Eine kurze Lebensspanne mit menstruellen Zyklen, Laktation und Parität reduzieren das Risiko für Ovarialkarzinome.

• Es besteht bisher kein klarer Zusammenhang zwischen Infertilität und dem Risiko für ein Ovarialkarzinom, er scheint jedoch von der Infertilitätsursache abhängig zu sein.

• Literatur

• 1 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29
• 2 Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer – shifting the paradigm. Hum Pathol 2011; 42: 918-931
• 3 Gershenson DM, Silva EG, Tortolero-Luna G et al. Serous borderline tumors of the ovary with noninvasive peritoneal implants. Cancer 1998; 83: 2157-2163
• 4 Singer G, Kurman RJ, Chang HW et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002; 160: 1223-1228
• 5 Singer G, Oldt 3rd R, Cohen Y et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003; 95: 484-486
• 6 Ho CL, Kurman RJ, Dehari R et al. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 2004; 64: 6915-6918
• 7 Anglesio MS, Arnold JM, George J et al. Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res 2008; 6: 1678-1690
• 8 Malpica A, Deavers MT, Lu K et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004; 28: 496-504
• 9 Ahmed AA, Etemadmoghadam D, Temple J et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010; 221: 49-56
• 10 [Anonym] Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615
• 11 Kelemen LE, Kobel M. Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. Lancet Oncol 2011; 12: 1071-1080
• 12 Hart WR. Mucinous tumors of the ovary: a review. Int J Gynecol Pathol 2005; 24: 4-25
• 13 Enomoto T, Weghorst CM, Inoue M et al. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 1991; 139: 777-785
• 14 Gemignani ML, Schlaerth AC, Bogomolniy F et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 2003; 90: 378-381
• 15 Mayr D, Hirschmann A, Lohrs U et al. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 2006; 103: 883-887
• 16 Mok SC, Bell DA, Knapp RC et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 1993; 53: 1489-1492
• 17 Kurman RJ, Visvanathan K, Roden R et al. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 2008; 198: 351-356
• 18 Landen jr. CN, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008; 26: 995-1005
• 19 Kuo KT, Mao TL, Jones S et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009; 174: 1597-1601
• 20 Yamamoto S, Tsuda H, Takano M et al. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. J Pathol 2011; 225: 189-194
• 21 Yamamoto S, Tsuda H, Takano M et al. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol 2012; 25: 615-624
• 22 Kuo KT, Mao TL, Chen X et al. DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res 2010; 16: 1997-2008
• 23 Wu R, Zhai Y, Fearon ER et al. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 2001; 61: 8247-8255
• 24 Moreno-Bueno G, Gamallo C, Perez-Gallego L et al. Beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn Mol Pathol 2001; 10: 116-122
• 25 Wiegand KC, Shah SP, Al-Agha OM et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363: 1532-1543
• 26 Obata K, Morland SJ, Watson RH et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998; 58: 2095-2097
• 27 Saito M, Okamoto A, Kohno T et al. Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int J Cancer 2000; 85: 160-165
• 28 Sato N, Tsunoda H, Nishida M et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000; 60: 7052-7056
• 29 Prowse AH, Manek S, Varma R et al. Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer 2006; 119: 556-562
• 30 Kang SK, Choi KC, Cheng KW et al. Role of gonadotropin-releasing hormone as an autocrine growth factor in human ovarian surface epithelium. Endocrinology 2000; 141: 72-80
• 31 Emons G, Pahwa GS, Brack C et al. Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol 1989; 25: 215-221
• 32 Emons G, Ortmann O, Pahwa GS et al. Intracellular actions of gonadotropic and peptide hormones and the therapeutic value of GnRH-agonists in ovarian cancer. Acta Obstet Gynecol Scand Suppl 1992; 155: 31-38
• 33 Irmer G, Burger C, Muller R et al. Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma. Cancer Res 1995; 55: 817-822
• 34 So WK, Cheng JC, Poon SL et al. Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview. FEBS J 2008; 275: 5496-5511
• 35 Emons G, Ortmann O, Becker M et al. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 1993; 53: 5439-5446
• 36 Emons G, Pahwa GS, Ortmann O et al. LHRH-receptors and LHRH-agonist treatment in ovarian cancer: an overview. J Steroid Biochem Mol Biol 1990; 37: 1003-1006
• 37 Emons G, Weiss S, Ortmann O et al. LHRH might act as a negative autocrine regulator of proliferation of human ovarian cancer. Eur J Endocrinol 2000; 142: 665-670
• 38 Ling Poon S, Lau MT, Hammond GL et al. Gonadotropin-releasing hormone-II increases membrane type I metalloproteinase production via beta-catenin signaling in ovarian cancer cells. Endocrinology 2011; 152: 764-772
• 39 Parrott JA, Doraiswamy V, Kim G et al. Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol Cell Endocrinol 2001; 172: 213-222
• 40 Lu JJ, Zheng Y, Kang X et al. Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer. Gynecol Oncol 2000; 79: 158-168
• 41 Chudecka-Glaz A, Rzepka-Gorska I, Kosmowska B. Gonadotropin (LH, FSH) levels in serum and cyst fluid in epithelial tumors of the ovary. Arch Gynecol Obstet 2004; 270: 151-156
• 42 Choi JH, Choi KC, Auersperg N et al. Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 2004; 89: 5508-5516
• 43 Tashiro H, Katabuchi H, Begum M et al. Roles of luteinizing hormone/chorionic gonadotropin receptor in anchorage-dependent and -independent growth in human ovarian surface epithelial cell lines. Cancer Sci 2003; 94: 953-959
• 44 Ji Q, Liu PI, Chen PK et al. Follicle stimulating hormone-induced growth promotion and gene expression profiles on ovarian surface epithelial cells. Int J Cancer 2004; 112: 803-814
• 45 Lau MT, Wong AS, Leung PC. Gonadotropins induce tumor cell migration and invasion by increasing cyclooxygenases expression and prostaglandin E(2) production in human ovarian cancer cells. Endocrinology 2010; 151: 2985-2993
• 46 Schiffenbauer YS, Meir G, Maoz M et al. Gonadotropin stimulation of MLS human epithelial ovarian carcinoma cells augments cell adhesion mediated by CD44 and by alpha(v)-integrin. Gynecol Oncol 2002; 84: 296-302
• 47 Zygmunt M, Herr F, Keller-Schoenwetter S et al. Characterization of human chorionic gonadotropin as a novel angiogenic factor. J Clin Endocrinol Metab 2002; 87: 5290-5296
• 48 Wang J, Luo F, Lu JJ et al. VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors. Int J Cancer 2002; 97: 163-167
• 49 Heinonen PK, Koivula T, Rajaniemi H et al. Peripheral and ovarian venous concentrations of steroid and gonadotropin hormones in postmenopausal women with epithelial ovarian tumors. Gynecol Oncol 1986; 25: 1-10
• 50 Cunat S, Rabenoelina F, Daures JP et al. Aromatase expression in ovarian epithelial cancers. J Steroid Biochem Mol Biol 2005; 93: 15-24
• 51 Brandenberger AW, Tee MK, Jaffe RB. Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. J Clin Endocrinol Metab 1998; 83: 1025-1028
• 52 Galtier-Dereure F, Capony F, Maudelonde T et al. Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1. J Clin Endocrinol Metab 1992; 75: 1497-1502
• 53 Song J, Fadiel A, Edusa V et al. Estradiol-induced ezrin overexpression in ovarian cancer: a new signaling domain for estrogen. Cancer Lett 2005; 220: 57-65
• 54 Keith Bechtel M, Bonavida B. Inhibitory effects of 17beta-estradiol and progesterone on ovarian carcinoma cell proliferation: a potential role for inducible nitric oxide synthase. Gynecol Oncol 2001; 82: 127-138
• 55 Bai W, Oliveros-Saunders B, Wang Q et al. Estrogen stimulation of ovarian surface epithelial cell proliferation. In Vitro Cell Dev Biol Anim 2000; 36: 657-666
• 56 Syed V, Ulinski G, Mok SC et al. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 2001; 61: 6768-6776
• 57 Bardin A, Moll F, Margueron R et al. Transcriptional and posttranscriptional regulation of fibulin-1 by estrogens leads to differential induction of messenger ribonucleic acid variants in ovarian and breast cancer cells. Endocrinology 2005; 146: 760-768
• 58 Yousef GM, Diamandis EP. Kallikreins, steroid hormones, and ovarian cancer: is there a link?. Minerva Endocrinol 2002; 27: 157-166
• 59 Simpson BJ, Langdon SP, Rabiasz GJ et al. Estrogen regulation of transforming growth factor-alpha in ovarian cancer. J Steroid Biochem Mol Biol 1998; 64: 137-145
• 60 Wimalasena J, Meehan D, Dostal R et al. Growth factors interact with estradiol and gonadotropins in the regulation of ovarian cancer cell growth and growth factor receptors. Oncol Res 1993; 5: 325-337
• 61 Krywicki RF, Figueroa JA, Jackson JG et al. Regulation of insulin-like growth factor binding proteins in ovarian cancer cells by oestrogen. Eur J Cancer 1993; 29?A: 2015-2019
• 62 Mukherjee K, Syed V, Ho SM. Estrogen-induced loss of progesterone receptor expression in normal and malignant ovarian surface epithelial cells. Oncogene 2005; 24: 4388-4400
• 63 Kang SK, Choi KC, Tai CJ et al. Estradiol regulates gonadotropin-releasing hormone (GnRH) and its receptor gene expression and antagonizes the growth inhibitory effects of GnRH in human ovarian surface epithelial and ovarian cancer cells. Endocrinology 2001; 142: 580-588
• 64 Treeck O, Pfeiler G, Mitter D et al. Estrogen receptor beta-1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J Endocrinol 2007; 193: 421-433
• 65 Ho SM. Estrogen, progesterone, and epithelial ovarian cancer. Reprod Biol Endocrinol 2003; 1: 73
• 66 Fauvet R, Dufournet Etienne C, Poncelet C et al. Effects of progesterone and anti-progestin (mifepristone) treatment on proliferation and apoptosis of the human ovarian cancer cell line, OVCAR-3. Oncol Rep 2006; 15: 743-748
• 67 Syed V, Mukherjee K, Godoy-Tundidor S et al. Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression. J Cell Biochem 2007; 102: 442-452
• 68 Hua K, Feng W, Cao Q et al. Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer. Int J Oncol 2008; 33: 959-967
• 69 Peluso JJ. Progesterone signaling mediated through progesterone receptor membrane component-1 in ovarian cells with special emphasis on ovarian cancer. Steroids 2011; 76: 903-909
• 70 Takahashi A, Kato K, Kuboyama A et al. Induction of senescence by progesterone receptor-B activation in response to cAMP in ovarian cancer cells. Gynecol Oncol 2009; 113: 270-276
• 71 Gabra H, Langdon SP, Watson JE et al. Loss of heterozygosity at 11q22 correlates with low progesterone receptor content in epithelial ovarian cancer. Clin Cancer Res 1995; 1: 945-953
• 72 Davis M, Hitchcock A, Foulkes WD et al. Refinement of two chromosome 11 q regions of loss of heterozygosity in ovarian cancer. Cancer Res 1996; 56: 741-744
• 73 Zhao D, Zhang F, Zhang W et al. Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 2013; 23: 25-33
• 74 Cardillo MR, Petrangeli E, Aliotta N et al. Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. J Exp Clin Cancer Res 1998; 17: 231-237
• 75 Edmondson RJ, Monaghan JM, Davies BR. The human ovarian surface epithelium is an androgen responsive tissue. Br J Cancer 2002; 86: 879-885
• 76 Giovannucci E, Stampfer MJ, Krithivas K et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A 1997; 94: 3320-3323
• 77 Li AJ, Elmore RG, Pavelka JC et al. Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology. Gynecol Oncol 2007; 107: 420-423
• 78 Evangelou A, Jindal SK, Brown TJ et al. Down-regulation of transforming growth factor beta receptors by androgen in ovarian cancer cells. Cancer Res 2000; 60: 929-935
• 79 Sheach LA, Adeney EM, Kucukmetin A et al. Androgen-related expression of G-proteins in ovarian cancer. Br J Cancer 2009; 101: 498-503
• 80 Ilekis JV, Connor JP, Prins GS et al. Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol 1997; 66: 250-254
• 81 Fathalla MF. Incessant ovulation – a factor in ovarian neoplasia?. Lancet 1971; 2: 163
• 82 Schildkraut JM, Bastos E, Berchuck A. Relationship between lifetime ovulatory cycles and overexpression of mutant p 53 in epithelial ovarian cancer. J Natl Cancer Inst 1997; 89: 932-938
• 83 Kuhn E, Kurman RJ, Shih IM. Ovarian cancer is an imported disease: fact or fiction?. Curr Obstet Gynecol Rep 2012; 1: 1-9
• 84 Przybycin CG, Kurman RJ, Ronnett BM et al. Are all pelvic (nonuterine) serous carcinomas of tubal origin?. Am J Surg Pathol 2010; 34: 1407-1416
• 85 Kuhn E, Kurman RJ, Vang R et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma – evidence supporting the clonal relationship of the two lesions. J Pathol 2012; 226: 421-426
• 86 Marquez RT, Baggerly KA, Patterson AP et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 2005; 11: 6116-6126
• 87 Murdoch WJ, Martinchick JF. Oxidative damage to DNA of ovarian surface epithelial cells affected by ovulation: carcinogenic implication and chemoprevention. Exp Biol Med (Maywood) 2004; 229: 546-552
• 88 Merritt MA, Cramer DW. Molecular pathogenesis of endometrial and ovarian cancer. Cancer Biomark 2010; 9: 287-305
• 89 Massuger L, Roelofsen T, Ham M et al. The origin of serous ovarian cancer may be found in the uterus: a novel hypothesis. Med Hypotheses 2010; 74: 859-861
• 90 Baergen RN, Warren CD, Isacson C et al. Early uterine serous carcinoma: clonal origin of extrauterine disease. Int J Gynecol Pathol 2001; 20: 214-219
• 91 Kupryjanczyk J, Thor AD, Beauchamp R et al. Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease. Mod Pathol 1996; 9: 166-173
• 92 Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983; 71: 717-721
• 93 Vanderhyden BC, Shaw TJ, Ethier JF. Animal models of ovarian cancer. Reprod Biol Endocrinol 2003; 1: 67
• 94 Blaakaer J, Baeksted M, Micic S et al. Gonadotropin-releasing hormone agonist suppression of ovarian tumorigenesis in mice of the Wx/Wv genotype. Biol Reprod 1995; 53: 775-779
• 95 Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998; 90: 1774-1786
• 96 Silva EG, Tornos C, Fritsche jr. HA et al. The induction of benign epithelial neoplasms of the ovaries of guinea pigs by testosterone stimulation: a potential animal model. Mod Pathol 1997; 10: 879-883
• 97 Nishizuka Y, Sakakura T, Tsujimura T et al. Steroid biosynthesis in vitro by dysgenetic ovaries induced by neonatal thymectomy in mice. Endocrinology 1973; 93: 786-792
• 98 Helzlsouer KJ, Alberg AJ, Gordon GB et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. J Am Med Assoc 1995; 274: 1926-1930
• 99 Wynder EL, Dodo H, Barber HR. Epidemiology of cancer of the ovary. Cancer 1969; 23: 352-370
• 100 Sonnichsen AC, Lindlacher U, Richter WO et al. [Obesity, body fat distribution and the incidence of breast, cervical, endometrial and ovarian carcinomas]. Dtsch Med Wochenschr 1990; 115: 1906-1910
• 101 [Anonym] Ovarian cancer and body size: individual participant meta-analysis including 25, 157 women with ovarian cancer from 47 epidemiological studies. PLoS Med 2012; 9: e1001200
• 102 Olsen CM, Green AC, Nagle CM et al. Epithelial ovarian cancer: testing the ʼandrogens hypothesis . Endocr Relat Cancer 2008; 15: 1061-1068
• 103 Kotsopoulos J, Baer HJ, Tworoger SS. Anthropometric measures and risk of epithelial ovarian cancer: results from the nurses health study. Obesity (Silver Spring) 2010; 18: 1625-1631
• 104 Lahmann PH, Cust AE, Friedenreich CM et al. Anthropometric measures and epithelial ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2010; 126: 2404-2415
• 105 Tung KH, Goodman MT, Wu AH et al. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 2003; 158: 629-638
• 106 Tsilidis KK, Allen NE, Key TJ et al. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 2011; 105: 1436-1442
• 107 Gong TT, Wu QJ, Vogtmann E et al. Age at menarche and risk of ovarian cancer: A meta-analysis of epidemiological studies. Int J Cancer 2013; 132: 2894-2900
• 108 Braem MG, Onland-Moret NC, van den Brandt PA et al. Reproductive and hormonal factors in association with ovarian cancer in the Netherlands cohort study. Am J Epidemiol 2010; 172: 1181-1189
• 109 Soegaard M, Jensen A, Hogdall E et al. Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Biomarkers Prev 2007; 16: 1160-1166
• 110 Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136: 1184-1203
• 111 Jordan SJ, Siskind V. C Green A et al. Breastfeeding and risk of epithelial ovarian cancer. Cancer Causes Control 2010; 21: 109-116
• 112 Gates MA, Rosner BA, Hecht JL et al. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol 2010; 171: 45-53
• 113 Titus-Ernstoff L, Perez K, Cramer DW et al. Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer 2001; 84: 714-721
• 114 Purdie DM, Siskind V, Bain CJ et al. Reproduction-related risk factors for mucinous and nonmucinous epithelial ovarian cancer. Am J Epidemiol 2001; 153: 860-864
• 115 McNeilly AS. Lactational control of reproduction. Reprod Fertil Dev 2001; 13: 583-590
• 116 Riman T, Dickman PW, Nilsson S et al. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol 2002; 156: 363-373
• 117 Merrill RM, Fugal S, Novilla LB et al. Cancer risk associated with early and late maternal age at first birth. Gynecol Oncol 2005; 96: 583-593
• 118 Risch HA, Marrett LD, Jain M et al. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol 1996; 144: 363-372
• 119 Kvale G, Heuch I, Nilssen S et al. Reproductive factors and risk of ovarian cancer: a prospective study. Int J Cancer 1988; 42: 246-251
• 120 Whiteman DC, Murphy MF, Cook LS et al. Multiple births and risk of epithelial ovarian cancer. J Natl Cancer Inst 2000; 92: 1172-1177
• 121 Kurian AW, Balise RR, McGuire V et al. Histologic types of epithelial ovarian cancer: have they different risk factors?. Gynecol Oncol 2005; 96: 520-530
• 122 Jordan SJ, Green AC, Nagle CM et al. Beyond parity: association of ovarian cancer with length of gestation and offspring characteristics. Am J Epidemiol 2009; 170: 607-614
• 123 Brinton LA, Melton 3rd LJ, Malkasian jr. GD et al. Cancer risk after evaluation for infertility. Am J Epidemiol 1989; 129: 712-722
• 124 Rodriguez C, Tatham LM, Calle EE et al. Infertility and risk of fatal ovarian cancer in a prospective cohort of US women. Cancer Causes Control 1998; 9: 645-651
• 125 Rossing MA, Tang MT, Flagg EW et al. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol 2004; 160: 1070-1078
• 126 Jensen A, Sharif H, Olsen JH et al. Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. Am J Epidemiol 2008; 168: 49-57
• 127 Ness RB, Cramer DW, Goodman MT et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002; 155: 217-224
• 128 Venn A, Watson L, Bruinsma F et al. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 1999; 354: 1586-1590
• 129 Pearce CL, Templeman C, Rossing MA et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012; 13: 385-394
• 130 Schildkraut JM, Schwingl PJ, Bastos E et al. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 1996; 88: 554-559
• 131 Chittenden BG, Fullerton G, Maheshwari A et al. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online 2009; 19: 398-405
• 132 Pierpoint T, McKeigue PM, Isaacs AJ et al. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998; 51: 581-586
• 133 Brinton LA, Moghissi KS, Westhoff CL et al. Cancer risk among infertile women with androgen excess or menstrual disorders (including polycystic ovary syndrome). Fertil Steril 2010; 94: 1787-1792
• 134 Rebar R, Judd HL, Yen SS et al. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest 1976; 57: 1320-1329
• 135 Baird DT, Corker CS, Davidson DW et al. Pituitary-ovarian relationships in polycystic ovary syndrome. J Clin Endocrinol Metab 1977; 45: 798-801
• 136 Auersperg N. Ovarian surface epithelium as a source of ovarian cancers: unwarranted speculation or evidence-based hypothesis?. Gynecol Oncol 2013; 130: 246-251